MeiraGTx

MeiraGTx is a clinical-stage genetic medicines company founded in 2015. It specializes in developing gene therapies for severe inherited and acquired diseases, focusing on conditions with significant unmet medical needs, such as inherited eye diseases, Parkinson’s disease, and radiation-induced xerostomia. The company has a broad pipeline of gene therapy candidates, including four late-stage clinical programs. MeiraGTx develops advanced viral vectors to ensure effective and safe delivery of therapeutic genes. It operates five global manufacturing facilities, including two licensed for GMP viral vector production, allowing for comprehensive control from research to commercial production. A key innovation is its riboswitch gene regulation platform, which enables precise control of gene expression in vivo. This technology is applied in various therapies, including those for metabolic peptides and cell therapies for cancer and chronic pain. The company collaborates with healthcare providers and research institutions to address rare genetic disorders and expand treatment options for more common diseases. In 2025, MeiraGTx entered a joint venture with Hologen to develop gene therapies for Parkinson’s disease and obesity, enhancing its capabilities in manufacturing and clinical development.